← Eichor
Study identifier: NCT03530852 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB

Condition: Short Bowel Syndrome · Malabsorption  ·  Sponsor: Boston Children's Hospital

PhaseNA
Planned participants32
Who can joinAll sexes, 2 Years to 18 Years
Healthy volunteersNo

About this study

Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver failure. Tube feeding directly to the small intestine avoids the complications of IV nutrition, but fats are not fully digestible due to inadequate bowel function. We propose to predigest the fat using a small cartridge attached to the feeding tube to allow for rapid absorption with the possibility of reducing or eliminating the need for intravenous nutrition

This description comes directly from the study's public registry record.

Talk to the study team

Mark Puder, MD, PhD  ·  617-355-1838  ·  mark.puder@childrens.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Children's Hospital Los AngelesLos Angeles, California, United StatesRecruiting
Boston Children's HospitalBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03530852